OncoMatch/Clinical Trials/NCT06150898
Ketorolac and Pregabalin Effects on breaSt Cancer (KePreSt)
Is NCT06150898 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Ketorolac 10 Mg Oral Tablet and Pregabalin 75mg for early-stage breast cancer.
Treatment: Ketorolac 10 Mg Oral Tablet · Pregabalin 75mg · Omeprazole 20mg Capsule — Out of all proportion to its short duration, the perioperative period is critical in determining the long-term outcome of cancer. To contribute to a better understanding of the neural and inflammatory mechanisms underlying this issue, we aim to implement a novel intervention based on the preoperative use of non-steroidal anti-inflammatory drugs (NSAIDs) with or without an anti-epileptic drug. Our goal is to understand and transform the perioperative window from being a facilitator of metastatic progression to arresting and/or eliminating residual disease using repurposing drugs
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Biomarker criteria
Required: ESR1 overexpression (IHC ≥ 1% and/or Allred score ≥ 3)
estrogen receptor positive as per ... guidelines ... ER-positive is defined as having an immunohistochemistry (IHC) of 1% or more and/or Allred score of 3 or more
Disease stage
Required: Stage I, II, III
Performance status
ASA 0–2
Prior therapy
Cannot have received: neoadjuvant therapy
Neoadjuvant BC therapy
Lab requirements
Blood counts
platelet count ≥ 100,000/μL; absolute neutrophil count ≥ 1000/μL
Kidney function
GFR ≥ 90 ml/min/1.73m² and serum creatinine ≤ 442 μmol/l (≤ 5 mg/dL); no single kidney or previous renal surgery
Liver function
total serum bilirubin < 2 x ULN (unless Gilbert syndrome); ALT < 2 x ULN; ALP < 2.5 x ULN
Inadequate liver function (defined as total serum bilirubin ≥ 2 x upper limit of normal (ULN<1.2 mg/dl) - unless documented Gilbert syndrome- AND Alanine Aminotransferase (ALT) ≥ 2 x ULN (ULN <32 UI/l and ULN <33 UI/l, respectively) AND Alkaline phosphatase (ALP) ≥ 2.5 x ULN (ULN=104 UI/l)); Renal impairment (defined as GFR<90ml/min/1.73m² or serum creatinine > 442 μmol/l or > 5 mg/dL) or single kidney or previous renal surgery; Inadequate bone marrow function (defined as absolute neutrophil count <1000/μL and platelet count <100'000/μL)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify